These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2552467)

  • 1. R68070, a combined thromboxane/endoperoxide receptor antagonist (TRA) and thromboxane synthase inhibitor (TSI), prolongs the bleeding time more than aspirin in man.
    Hoet B; Arnout J; Vermylen J
    Prog Clin Biol Res; 1989; 301():573-7. PubMed ID: 2552467
    [No Abstract]   [Full Text] [Related]  

  • 2. R68070, a combined thromboxane/endoperoxide receptor antagonist and thromboxane synthase inhibitor, inhibits human platelet activation in vitro and in vivo: a comparison with aspirin.
    Hoet B; Falcon C; De Reys S; Arnout J; Deckmyn H; Vermylen J
    Blood; 1990 Feb; 75(3):646-53. PubMed ID: 2153424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade, combined in one molecule.
    De Clerck F; Beetens J; de Chaffoy de Courcelles D; Vercammen E; Freyne E; Janssen PA
    Prog Clin Biol Res; 1989; 301():567-72. PubMed ID: 2529556
    [No Abstract]   [Full Text] [Related]  

  • 4. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--I. Biochemical profile in vitro.
    De Clerck F; Beetens J; de Chaffoy de Courcelles D; Freyne E; Janssen PA
    Thromb Haemost; 1989 Feb; 61(1):35-42. PubMed ID: 2546278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
    Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
    Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo.
    De Clerck F; Beetens J; Van de Water A; Vercammen E; Janssen PA
    Thromb Haemost; 1989 Feb; 61(1):43-9. PubMed ID: 2526385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ridogrel inhibits systemic and renal formation of thromboxane A2 and antagonizes platelet thromboxane A2/prostaglandin endoperoxide receptors upon chronic administration to man.
    Weber C; Beetens JR; Tegtmeier F; Van Rooy P; Vercammen E; Wouters L; De Clerck F
    Thromb Haemost; 1992 Aug; 68(2):214-20. PubMed ID: 1412169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological manipulation of the thromboxane pathway in blood platelets.
    Hoet B; Deckmyn H; Arnout J; Vermylen J
    Blood Coagul Fibrinolysis; 1990 Jun; 1(2):225-33. PubMed ID: 2130935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor.
    Hoet B; Arnout J; Deckmyn H; Vermylen J
    Thromb Haemost; 1993 Nov; 70(5):822-5. PubMed ID: 8128441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism.
    Gresele P; Arnout J; Deckmyn H; Huybrechts E; Pieters G; Vermylen J
    J Clin Invest; 1987 Nov; 80(5):1435-45. PubMed ID: 2960694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of GR32191, R68070 and CV-4151 upon U-46619- and collagen-induced platelet aggregation in vitro and ex vivo.
    Watts IS; White BP; Wharton KA; Lumley P
    Br J Pharmacol; 1989 Dec; 98 Suppl():842P. PubMed ID: 2611538
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of combined thromboxane synthetase inhibition/thromboxane receptor antagonism in two models of sudden cardiac death in the canine: limited role for thromboxane.
    Kitzen JM; Chi LG; Uprichard AC; Lucchesi BR
    J Cardiovasc Pharmacol; 1990 Jul; 16(1):68-80. PubMed ID: 1696668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual inhibition of thromboxane A2 synthesis and thromboxane A2/prostaglandin endoperoxide receptors by ridogrel: anti-thrombotic effect in vivo in rat mesenteric arteries.
    Bourgain RH; Andries R; Decuyper K; De Clerck F
    J Lipid Mediat; 1991; 3(1):3-11. PubMed ID: 1837488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ridogrel, a combined thromboxane synthase inhibitor and receptor blocker, decreases elevated plasma beta-thromboglobulin levels in patients with documented peripheral arterial disease.
    Hoet B; Arnout J; Van Geet C; Deckmyn H; Verhaeghe R; Vermylen J
    Thromb Haemost; 1990 Aug; 64(1):87-90. PubMed ID: 2148849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
    Vezza R; Nenci GG; Gresele P
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of thromboxane A2 synthase inhibition, singly or combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on occlusive thrombosis elicited by endothelial cell injury or by deep vascular damage in canine coronary arteries.
    Vandeplassche G; Hemans C; Van de Water A; Xhonneux R; Wouters L; Van Ammel K; De Clerck F
    Circ Res; 1991 Aug; 69(2):313-24. PubMed ID: 1830517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT).
    Circulation; 1994 Feb; 89(2):588-95. PubMed ID: 8313547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of N,N'-bis(3-picolyl)-4-methoxy-isophtalamide (picotamide) as a dual thromboxane synthase inhibitor/thromboxane A2 receptor antagonist in human platelets.
    Gresele P; Deckmyn H; Arnout J; Nenci GG; Vermylen J
    Thromb Haemost; 1989 Jun; 61(3):479-84. PubMed ID: 2552606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostaglandins and hemostasis: an overview.
    Stuart MJ
    Adv Pediatr; 1983; 30():321-64. PubMed ID: 6231843
    [No Abstract]   [Full Text] [Related]  

  • 20. Protective effects of a combination thromboxane synthesis inhibitor-receptor antagonist, R-68070, during murine traumatic shock.
    Aoki N; Johnson G; Siegfried MR; Lefer AM
    Eicosanoids; 1989; 2(3):169-74. PubMed ID: 2534278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.